Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation. The two companies expect to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for the potential treatment of autoimmune diseases. The companies plan to use Medarex's UltiMAb Human Antibody Development System(R) to generate antibodies for research and possible development.
Under the terms of the agreement, Medarex and Mitsubishi Pharma will share research responsibilities for any antibodies generated through the collaboration. Other terms of the agreement were not disclosed.
"We are very much pleased to work with Medarex," said Dr. Tohru Nakajima, Executive Officer/Division Manager of the Pharmaceutical Research Division for Mitsubishi Pharma. "We will gain access to excellent expertise that provides us with the potential advancement of novel therapeutics for autoimmune diseases."
"We are pleased to have this opportunity to partner with Mitsubishi Pharma Corporation and its research team and to work together to potentially discover new antibody therapeutics," said Irwin Lerner, Interim President and CEO of Medarex.
Source: PR Newswire